Insmed

Yahoo Finance • 2 days ago

PAA Stock Crowded With Sellers

In trading on Thursday, shares of Plains All American Pipeline LP (Symbol: PAA) entered into oversold territory, changing hands as low as $16.11 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a... Full story

Yahoo Finance • 9 days ago

Ohio Retirement Fund Invests in Insmed Incorporated (INSM)

Insmed Incorporated (NASDAQ:INSM) is among the most promising biotech stocks to buy according to hedge funds. In the second quarter, Public Employees Retirement System of Ohio acquired a new stake in Insmed Incorporated (NASDAQ:INSM) throu... Full story

Yahoo Finance • 11 days ago

Stocks of possible M&A targets have been crushing the market. Goldman says these 6 are the most likely to get bought.

Mergers and acquisitions activity has surged in 2025, with a 29% increase in deal value. Goldman Sachs predicts another 15% rise in M&A deals in 2026, boosting candidate valuations. It flagged a list of firms it sees as M&A targets. Here a... Full story

Yahoo Finance • 11 days ago

Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9%

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Insmed Incorporated is one of them. Insmed Incorporated (NASDAQ:INSM) tops our list for being one of the best performing stocks. It is a biopharmace... Full story

Yahoo Finance • 19 days ago

Validea Detailed Fundamental Analysis - INSM

Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. This momentum model looks fo... Full story

Yahoo Finance • 20 days ago

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT Session— —New Analysis from Phase 3 ASPEN Trial Examines Efficacy and Safety of B... Full story

Yahoo Finance • 23 days ago

Guru Fundamental Report for INSM

Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for... Full story

Yahoo Finance • 28 days ago

INSM Quantitative Stock Analysis - Benjamin Graham

Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology scree... Full story

Yahoo Finance • last month

Benjamin Graham Detailed Fundamental Analysis - INSM

Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology scree... Full story

Yahoo Finance • last month

Guru Fundamental Report for INSM - Benjamin Graham

Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology scree... Full story

Yahoo Finance • last month

Why United Therapeutics Catapulted 38%, Pulling Insmed, Liquidia With It

United Therapeutics stock catapulted Tuesday, pulling shares of rivals Insmed and Liquidia higher, on positive test results in IPF. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Health care stocks with the largest net increases in hedge fund popularity – Goldman Sachs

[Medical industry stock market graph chart] Rasi Bhadramani Hedge funds increased their overweight positioning in health care (NYSEARCA:XLV [https://seekingalpha.com/symbol/XLV]) despite a 7% decline in the sector during the second quarte... Full story

Yahoo Finance • 2 months ago

C3 AI downgraded, Capri upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Elevate Your Investing Strategy: Take advantage of TipR... Full story

Yahoo Finance • 2 months ago

AN2 Therapeutics’ SWOT analysis: stock’s potential amid pipeline setbacks

AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases, finds itself at a critical juncture following recent clinical trial results and strategi... Full story

Yahoo Finance • 2 months ago

Insmed downgraded at Morgan Stanley despite FDA nod for lung therapy

[Wall Street sign in Lower Manhattan, NYC] georgeclerk * Morgan Stanley downgraded Insmed (NASDAQ:INSM [https://seekingalpha.com/symbol/INSM]) to Equal Weight from Overweight on Wednesday, citing concerns over the biotech’s valuation, a... Full story

Yahoo Finance • 2 months ago

Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval

Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a devastating lung condition. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Insmed outlines $405M–$425M ARIKAYCE revenue target as brensocatib nears launch and pipeline advances

Earnings Call Insights: Insmed Incorporated (INSM) Q2 2025 MANAGEMENT VIEW * William H. Lewis, President, CEO & Chairman, highlighted, "Insmed is now three for three, all three of our late-stage assets, ARIKAYCE, brensocatib and TPIP a... Full story

Yahoo Finance • 2 months ago

Insmed Q2 2025 Earnings Preview

* Insmed (NASDAQ:INSM [https://seekingalpha.com/symbol/INSM]) is scheduled to announce Q2 earnings results on Thursday, August 7th, before market open. * The consensus EPS Estimate is -$1.31 [https://seekingalpha.com/symbol/INSM/earnin... Full story

Yahoo Finance • 2 months ago

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

NetworkNewsWire Editorial Coverage NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than... Full story

Yahoo Finance • 2 months ago

Strong Drug Development Momentum Lifted Insmed Incorporated (INSM) in Q2

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a... Full story